Overview

• Johnson & Johnson reported Q1 2025 revenue of $21.89 billion and adjusted EPS of $2.77, surpassing Wall Street expectations.
• The company's cancer drug portfolio, particularly Darzalex, saw a 20% year-over-year sales increase, generating $3.24 billion in revenue.
• J&J raised its full-year revenue forecast to a range of $91.6 billion to $92.4 billion, up from its prior projection of $90.9 billion to $91.7 billion.
• Profit guidance was revised downward to $10.50–$10.70 per share, reflecting $400 million in tariff-related costs and dilution from its $14.6 billion acquisition of Intra-Cellular Therapies.
• While the innovative medicines unit exceeded revenue expectations, medtech segment growth fell slightly short of analyst estimates, with $8.02 billion in sales.